Summary of the Healio Article on Preimplantation Genetic Testing for Polygenic Risk (PGT-P)
This article from Healio details an interview with Dr.Sigal Klipstein regarding Preimplantation Genetic Testing for Polygenic risk (PGT-P), a technology aiming to assess embryo risk for diseases influenced by multiple genes (like heart disease, diabetes, and some cancers). Here’s a breakdown of the key takeaways:
* What is PGT-P? It’s a technology that attempts to predict an embryo’s risk for certain diseases based on its genetic profile.
* Why isn’t it ready for clinical use? Dr.klipstein states there’s currently a lack of evidence supporting its clinical usefulness, long-term safety, and predictive accuracy.Our understanding of how genes and environment interact to cause disease is incomplete, making the risk scores generated by PGT-P unreliable for making embryo selection decisions.
* What needs to happen before it is ready? Extensive further research is required to:
* validate if genetic profiles truly predict increased disease risk.
* Determine if the results are consistent across diverse populations.
* Understand how future medical advancements (new drugs,treatments) might impact the actual health outcomes of individuals with these genetic predispositions.
* Ethical Concerns: The article highlights concerns about potential for exacerbating health disparities and reducing genetic diversity.
* Alternatives: Currently validated preimplantation genetic testing options exist for aneuploidy (abnormal chromosome number),structural rearrangements,single-gene disorders,and specific known risk genes.
* Key Message: There’s no guarantee of a healthy baby with any technology. It’s important to avoid over-reliance on unproven methods and maintain realistic expectations.
In essence, the article presents a cautious view of PGT-P, emphasizing the need for rigorous research and ethical consideration before it can be responsibly implemented in clinical practice.
